DNTH vs REGN · rev $6.2M vs P/E 14, rev $14.34B
Dianthus Therapeutics Inc. (DNTH) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DNTH currently screens at market cap $4.40B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DNTH and REGN stock pages for the full models.
Not investment advice.